Biobeat Brings Leading Hypertension Voices to AHA Hypertension Scientific Sessions as Conversation Shifts to Cuffless 24-Hour Ambulatory Blood Pressure Monitoring

The expert panel will explore clinical evidence and practical application for cuffless 24-hour ambulatory blood pressure monitoring as it becomes the trusted way in hypertension care

BOCA RATON, Fla. and TEL AVIV, Israel, Oct. 6, 2026 /PRNewswire/ -- Biobeat, the company transforming hypertension management with its FDA-cleared, medical-grade, single-use, 24-hour ambulatory blood pressure monitoring (ABPM) sensor, today announced it will host an expert panel session and exhibit at the American Heart Association's Hypertension Scientific Sessions 2026. The panel, comprising leading voices in hypertension, will delve into the shift toward cuffless 24-hour ambulatory blood pressure monitoring as it enables healthcare professionals' to monitor and manage hypertension, while giving attendees a first look at new clinical data from a large multinational hypertensive cohort.

Hypertension affects nearly 50% of U.S. adults, and nearly 80% of them do not have it under control. A single office reading misses nighttime blood pressure and cannot reliably distinguish true hypertension from white-coat or masked hypertension, making the condition hard to measure accurately and manage effectively.

While 24-hour ambulatory blood pressure monitoring (ABPM) is the diagnostic standard for confirming hypertension, traditional ABPM monitors depend on a cuff that inflates repeatedly around the clock, including overnight. Repeated cuff inflation can cause discomfort and disturb sleep and may cause patients to cut the test short or refuse follow-up monitoring.

Biobeat's wireless, cuffless chest patch redefines monitoring by providing clinically meaningful blood pressure data for physicians to interpret and make actionable decisions. Worn for the full monitoring period, it captures 96 blood pressure measurements across 24 hours and automatically generates a physician-ready report with daytime and nighttime averages, dipping patterns, blood pressure load, and indicators of masked or white-coat hypertension.

At the AHA Hypertension Scientific Sessions, Biobeat will host a Learning Studio session titled "From Evidence to Practice: How Clinically Validated Cuffless 24-Hour Ambulatory BP Monitoring is Changing Hypertension Diagnosis and Management." The panel will explore the clinical validation of cuffless 24-hour blood pressure monitoring and its real-world use in hypertension care. Panelists will also share practical strategies for using full day-and-night blood pressure data to guide treatment decisions.

Panelists include:

• Gianfranco Parati, MD – Professor of Cardiovascular Medicine, University of Milano-Bicocca, and Scientific Director, Istituto Auxologico Italiano
• Ziad Zoghby, MD, MBA, FACP – Associate Professor of Medicine, Mayo Clinic
• Maria Carolina Delgado-Lelievre, MD – Founder and Director, Comprehensive Hypertension Center, University of Miami Health System
• Elias G. Hellou, MD –Cardiologist – Emek Medical Center, Afula, Israel & Research Collaborator, Mayo Clinic

"The question in hypertension is no longer whether 24-hour data matters, but how we make clinically validated 24-hour blood pressure data more accessible to healthcare professionals. Cuffless monitoring can provide measurements collected outside the office for healthcare professionals to use with patients who have suspected hypertension," said Arik Ben Ishay, CEO and Co-Founder of Biobeat. "Medical-grade, clinically validated cuffless monitoring shows what office readings miss so clinicians can act on it. This panel brings both the evidence and the real-life practice from leading voices in hypertension."

Biobeat's session will take place on Thursday, October 8, 2026, from 10:00 to 10:30 a.m. ET, in Regency Ballroom A&B at the Hyatt Regency Crystal City.

AHA Hypertension Scientific Sessions 2026 takes place October 7–11 at the Hyatt Regency Crystal City in Arlington, Virginia. Attendees can visit Biobeat at Booth 13 throughout the event to see the chest patch and physician reporting platform, and to speak with the team.

About Biobeat

Biobeat is a medical technology company bringing cuffless 24-hour ambulatory blood pressure monitoring technology for routine hypertension care. Its FDA-cleared, medical-grade ABPM platform combines a cuffless single-use chest-worn sensor, mobile app, and physician report to provide clinicians with blood pressure measurements collected over a 24-hour period showing how blood pressure behaves throughout a patient's day and during sleep, when accurate readings are most crucial for correct diagnosis and treatment. FDA-cleared for 24-hour ambulatory blood pressure monitoring, the platform supports healthcare professionals in hypertension diagnosis and management, with clinical validation studies published in the American Journal of Hypertension.

Media Contact

Mike Katznelson
Headline Media
[email protected]
+1 914 233 5302

SOURCE Biobeat